^
Association details:
| Biomarker: | EGFR G719X |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lazcluze (lazertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Excerpt:
...E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I) 4....
Trial ID:
Source:
Title:
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
Excerpt:
...G719X, S768I, L861Q, G719X + S768I, G719X + L861Q, L861Q + S768I, L747S, S720A, E709A, exon 18 deletion) without common EGFR mutations including exon 19 deletion, L858R, exon 20 insertion, or T790M....
Trial ID:
Less C2 evidence
Source:
Title:
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
Published date:
08/08/2023
Excerpt:
The overall response rate was 44.1%, and disease control rate was 85.3%. Progression-free survival was 7.69 months (95% CI 4.4 - NA). Based on the mutation subtype, the response rate was as follows: G719X (n=13, 53.8%), L861Q (n=11, 54.6%)...In this study, we observed the clinical benefit of 240mg Lazertinib in the treatment of naïve EGFR uncommon mutants. Among the mutations, G719X and L861Q showed promising outcomes, which are aligned with preclinical data.
